Contineum Therapeutics Inc (CTNM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.70-4.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTNM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers
CTNM — litigation filed
Dated 2026-04-30
Other Events. On April 30, 2026, the Company announced topline data from its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain. This Phase 1b, randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 chronic osteoarthritic pain (“COAP”) patients and 20 chronic low back pain (“CLBP”) patients). More information on this trial can be found at https://clinicaltrials.gov (NCT06810245). Safety and Tolerability The trial met its primary objective of assessing…
Why it matters: Updates on cash runway are critical for funding ongoing trials and operations. It shows financial health.
Watch forManagement says they have enough cash to run operations until mid-2029.
Also watch forManagement says the cash runway will be shorter than mid-2029.
Why it matters: Less net income loss shows better cost management. It also shows improvements in operations.
Supportive ifNet income losses in Q2 drop below -$14M, showing progress in reducing losses.
Worry ifNet income losses stay at -$14.46M in Q1. This shows continued challenges.
Why it matters: Enrollment progress in the PROPEL-IPF trial is key to advancing PIPE-791 for IPF. More patients enrolled means better chances for positive outcomes.
Supportive ifManagement says enrollment is steady. There are over 324 patients in the PROPEL-IPF trial.
Worry ifEnrollment stops or goes down. This shows possible problems with the trial's progress.
Why it matters: Better operating income is important for growth. It helps with making money.
Supportive ifOperating income is now less than -$16M in Q2. This shows better cost control.
Worry ifOperating income is still worse than -$16M. This shows ongoing problems.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$247 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $649 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,984 loss on $10,000 · 29.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Positive cash flow would show that Contineum is moving towards financial stability. This is key for long-term growth.
Supportive ifQ2 cash flow from operations turns positive, showing a shift in financial health.
Worry ifQ2 cash flow from operations is still negative. This shows ongoing financial problems.
Why it matters: A smaller net loss and lower costs show better financial health and efficiency.
Watch forNet loss goes down from $15.2 million in Q2 2026, showing better financial results.
Also watch forNet loss goes up or operating costs rise a lot, showing worse financial conditions.
Why it matters: The results will show the chance for future treatments. They will also affect investor trust.
Watch forThe Phase 1b trial shows positive results. This indicates that PIPE-791 is safe and effective.
Also watch forNegative trial results raise worries about the drug's success.
Why it matters: The trial results could impact the company's future prospects and stock performance.
Watch forGood updates on the trial show safety and effectiveness. This boosts investor confidence.
Also watch forBad updates or delays in the trial hurt investor feelings.
Why it matters: Updates on cash runway are key. They help us see the company's financial health and funding ability.
Worry ifCash and equivalents will stay above $230 million in the next quarterly report.
Less concerning ifCash and equivalents drop below $220 million in the next quarterly report.
Why it matters: Good data from the chronic pain trial could help develop PIPE-791 and its market.
Supportive ifManagement is thinking about the next steps for PIPE-791 based on new trial data.
Worry ifNegative feedback from trials that questions how well PIPE-791 works.